5-MeO-DMT

全球生物医药创新节奏持续加快，基因编辑技术迎来全新研究进展，多款创新药物获得FDA批准上市，行业大额并购交易接连落地，同时多家新锐公司正式亮相。 本文从科研突破、新药审批、产业交易、新锐企业四个维度，对近期重点行业资讯进行分类梳理，快速掌握行业最新动向。 一、科研前沿 | CRISPR工具靶向清除特定肿瘤细胞 CRISPR全新工具，可编程靶向清除特定肿瘤细胞 2026年5月，《Nature》发表一项CRISPR基因编辑重磅研究。研究团队对CRISPR酶Cas12a2进行工程化改造，使其能够特异性识别目标RNA序列；一旦识别靶标，该酶将对细胞内DNA进行非特异性切割，直接诱导靶细胞死亡。 研究团队利用该策略靶向携带TP53、KRAS突变癌细胞的RNA，在小鼠模型中实现肿瘤体积显著缩小，为突变驱动肿瘤的靶向治疗提供全新技术思路。 二、新药获批 | 3款获FDA批准，覆盖肿瘤血脂 近期FDA连续批准多款创新药物，覆盖乳腺癌、非小细胞肺癌、高胆固醇血症。 1. Revtorpyk（gedatolisib）: Celcuity开发的PI3K/mTOR双靶点激酶抑制剂，获批用于无 PIK3CA突变的晚期/转移性HR阳性、HER2阴性乳腺癌。 2. Jideytro（zidesamtinib）: Nuvalent开发的ROS1激酶抑制剂，获批用于ROS1基因异常驱动的转移性非小细胞肺癌。GSK已于近期完成对Nuvalent的收购。 3. Lipfendra（enlicitide）: 默克开发口服PCSK9抑制剂，获批用于成人低密度脂蛋白胆固醇升高的治疗。 三、产业交易 | 多笔布局自免、精神、肿瘤早筛 全球药企持续通过收购快速扩充管线，多笔大额交易落地，覆盖抑郁症、自身免疫病、癌症液体活检方向。 1. 礼来收购AtaiBeckley： 首付款28亿美元，交易总金额最高可达38亿美元。收购标的核心资产BPL 003，为mebufotenin衍生物，结构与裸盖菇素类似，开发适应症为抑郁症。 2. Argenx收购Forte Biosciences： 交易金额22亿美元，获得CD122拮抗抗体，用于斑秃、乳糜泻、移植物抗宿主病 (GVHD)、白癜风等多种自身免疫性疾病。 3. Tempus收购Personalis： 以15亿美元收购肿瘤检测企业Personalis。该公司聚焦血液肿瘤液体活检，依靠肿瘤DNA检测，服务癌症诊断、用药指导、复发监测。 四、新锐登场 近期两家新锐生物技术企业接连官宣大动作，管线分别源自国内药企授权和前沿递送技术平台： 01  Avere Therapeutics： 公司核心管线来自翰森制药授权引进，核心资产口服IL‑23R拮抗剂AVR‑001，首付款达1.2亿美元。 02  Nava Therapeutics： 专注开发新型脂质纳米颗粒 (LNP) 递送系统，重点面向体内CAR‑T 疗法，以 8900 万美元融资结束隐身模式。 免责声明：本文资讯整理自公开行业报道，仅作产业交流，不构成投资与研发建议。 END  阅读更多内容分享

iStock, dnapslvsk Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market. Fueled by rising policy support, unmet need and Big Pharma interest, psychedelic medicine is pushing toward the mainstream. Yet the path forward is littered with challenges, including the burdens imposed by additional U.S. regulations that apply to controlled substances. As the American market starts to take shape, manufacturers in countries that relaxed their rules earlier want to leverage their experience to win possible market share. This year will likely serve as a landmark in the long-gestating reemergence of psychedelics for treating serious mental illness in the U.S. Within a few months, President Donald Trump ordered U.S. agencies to accelerate access to psychedelics, the FDA finalized guidance on clinical trials of the drugs and Eli Lilly moved into the space by acquiring AtaiBeckley for $3.8 billion. Meanwhile, Resilient Pharmaceuticals—formerly known as Lykos Therapeutics— refiled for approval of its MDMA therapy without running the new trial requested by the FDA in a complete response letter. “The U.S. ... executive order from a couple months ago fast tracking approval for these drugs is really encouraging,” Sam Watson, CEO of BLS Pharmaceuticals, a life sciences company and manufacturer based in Australia, told BioSpace . “I expect European countries to start taking it more seriously and following suit.” Psychedelics Psychedelics on the cusp of market breakthrough as clinical, policy support grow While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap. August 10, 2026 · 8 min read · Tristan Manalac Read more The U.S. currently classifies MDMA and psilocybin as Schedule I substances, indicating that there is no currently accepted medical use for the drug and a high potential for abuse. Other countries have different classifications for MDMA—which while not a classic psychedelic, can be used to assist mental health therapy—and the magic mushroom–derived psilocybin. In 2022, Canada amended its regulations to allow healthcare practitioners to request access to restricted drugs, including MDMA and psilocybin. The following year, Australia rescheduled MDMA and psilocybin to permit prescribing for post-traumatic stress disorder and treatment-resistant depression, respectively. The changes created demand for companies able to supply MDMA and psilocybin in compliance with the good manufacturing practices (GMPs) that cover pharmaceutical production. Australia’s BLS Pharmaceuticals is among these companies. Having established capacity to serve the Australian market, BLS now aspires to expand its manufacturing footprint globally. “Given we’ve got the manufacturing infrastructure, the supply chain, we can supply to market a GMP-released pharmaceutical medicine—we can now export that overseas,” BLS CEO Watson said. “We can start supplying trials in the U.S., the U.K., Germany, Switzerland. That’s the next step for us.” Unlocking the US Optimi Health, a Canadian manufacturer of MDMA and psilocybin, recently used its IPO paperwork to set out what it will take to bring psychedelics to the U.S. The manufacturing process must meet the FDA’s GMP standards. Importers need a Drug Enforcement Administration (DEA) registration and a permit from the federal agency for each shipment, confirming compliance with U.S. regulations. Optimi’s IPO is fueling its efforts to enter the U.S., although the company told investors the market will likely take 12 months to unlock. For now, MDMA and psilocybin face “a significant degree” of DEA regulation because they are considered Schedule I substances, Optimi said. Rescheduling could open up the market. In preparation, Optimi plans to ensure that its manufacturing practices align with both Health Canada and FDA requirements. The company has two 10,000-square-foot, pharmaceutical-grade mushroom cultivation and drug processing facilities in British Columbia and has a Health Canada license for buying or making controlled materials used to synthesize MDMA. “The Canadians are quite far ahead in actually making the compounds,” Watson said. BLS sources APIs from U.S.-Canadian companies and does “the higher-value product manufacturing” under its GMP license, Watson said. Australian production of MDMA and psilocybin is shaped by quality standards for the drugs that the country’s regulatory agency published in 2024. The documents “laid a very solid framework,” Watson said. Building on those foundations, BLS is “very well positioned” to serve international markets from its base in Australia, Watson said, but is also working to add manufacturing capacity in Europe. The company is building a facility in the U.K. As well as using the site to supply medicinal cannabis, BLS intends to apply for a license to make MDMA and psilocybin products at the facility, Watson said. Psychedelics Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals. July 24, 2026 · 3 min read · Gabrielle Masson Read more The next chapter Evidence that therapy assisted by MDMA or psilocybin can benefit patients has helped fuel interest in using psychedelics to treat serious mental illnesses. Yet access to the drugs could be limited even if the regulatory barriers clear, given the potential for clinics’ capacity to constrain uptake. The MDMA therapy that the FDA rejected in 2024 was given at three sessions, each lasting about eight hours. AtaiBeckley, the biotech Lilly is buying, sought to mitigate such concerns by designing its formulation of the single-dose psychedelic 5-MeO-DMT to be given in a two-hour session. Watson sees an opportunity for delivery mechanisms and compounds that improve psychedelic administration, and believes that manufacturing capabilities established to support MDMA and psilocybin will remain relevant as the market evolves. “The infrastructure is built to make these sorts of products. Any data we’re collecting now on the existing APIs and delivery mechanisms is obviously going to help when building new delivery mechanisms, and potentially with the analogs,” Watson said. “That’s really the big opportunity for us, to start developing our own proprietary delivery mechanisms and compounds.”